Dynamic Advisor Solutions LLC lifted its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 58.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,055 shares of the company's stock after acquiring an additional 4,811 shares during the period. Dynamic Advisor Solutions LLC's holdings in AstraZeneca were worth $960,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in AZN. Opal Wealth Advisors LLC increased its position in AstraZeneca by 32.2% during the 1st quarter. Opal Wealth Advisors LLC now owns 4,868 shares of the company's stock valued at $358,000 after buying an additional 1,185 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in AstraZeneca by 1.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 311,600 shares of the company's stock valued at $22,903,000 after buying an additional 5,557 shares in the last quarter. Azzad Asset Management Inc. ADV increased its position in AstraZeneca by 1.4% during the 1st quarter. Azzad Asset Management Inc. ADV now owns 63,127 shares of the company's stock valued at $4,640,000 after buying an additional 895 shares in the last quarter. New England Research & Management Inc. increased its position in AstraZeneca by 159.3% during the 1st quarter. New England Research & Management Inc. now owns 15,950 shares of the company's stock valued at $1,172,000 after buying an additional 9,800 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC increased its position in AstraZeneca by 23.3% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 55,075 shares of the company's stock valued at $4,048,000 after buying an additional 10,422 shares in the last quarter. Institutional investors own 20.35% of the company's stock.
Analyst Upgrades and Downgrades
Separately, BNP Paribas began coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $85.00.
Read Our Latest Report on AZN
AstraZeneca Stock Down 0.3%
Shares of AstraZeneca stock traded down $0.21 on Thursday, reaching $70.76. The company's stock had a trading volume of 3,370,917 shares, compared to its average volume of 5,202,526. The company has a market capitalization of $219.45 billion, a price-to-earnings ratio of 16.38, a P/E/G ratio of 1.30 and a beta of 0.38. The firm's fifty day simple moving average is $70.15 and its two-hundred day simple moving average is $70.36. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.06 EPS. Equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
